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Abstract
Background: The transcription factor GATA3 has recently been shown to be necessary for
mammary gland morphogenesis and luminal cell differentiation. There is also an increasing body of
data linking GATA3 to the estrogen receptor α (ERα) pathway. Among these it was shown that
GATA3 associates with the promoter of the ERα gene and ERα can reciprocally associate with the
GATA3 gene. GATA3 has also been directly implicated in a differentiated phenotype in mouse
models of mammary tumourigenesis. The purpose of our study was to compare coexpressed
genes, by meta-analysis, of GATA3 and relate these to a similar analysis for ERα to determine the
depth of overlap.
Results: We have used a newly described method of meta-analysis of multiple cancer studies
within the Oncomine database, focusing here predominantly upon breast cancer studies. We
demonstrate that ERα and GATA3 reciprocally have the highest overlap with one another.
Furthermore, we show that when both coexpression meta-analysis lists for ERα and GATA3 are
compared there is a significant overlap between both and, like ERα, GATA3 coexpresses with ERα
pathway partners such as pS2 (TFF1), TFF3, FOXA1, BCL2, ERBB4, XBP1, NRIP1, IL6ST, keratin
18(KRT18) and cyclin D1 (CCND1). Moreover, as these data are derived from human tumour
samples this adds credence to previous cell-culture or murine based studies.
Conclusion: GATA3 is hypothesized to be integral to the ERα pathway given the following: (1)
The large overlap of coexpressed genes as seen by meta-analysis, between GATA3 and ERα, (2)
The highest coexpressing gene for GATA3 was ERα and vice-versa, (3) GATA3, like ERα,
coexpresses with many well-known ERα pathway partners such as pS2.
Background
While GATA3 has most intensively been studied in the
immune system [1] GATA3 is also expressed in other bio-
logical environments such as the human endometrium
epithelial cells, where levels are regulated in a cyclic man-
ner [2]. GATA3 levels are also considered a good prognos-
tic biomarker in breast tumours. Specifically, in the
luminal A subtype of breast cancer GATA3 has both a
favorable prognostic outcome, and the highest ERα and
GATA3 expression of all breast tumours [3]. Consistent
with this, basal-like tumours have the lowest GATA3
expression and the worst prognosis. GATA3 has also been
shown in murine models to be essential to the develop-
ment and maintenance of mammary luminal cells [4,5].
There is also tentative data showing that different poly-
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morphisms of the GATA3 gene may associate with differ-
ential susceptibility to breast cancer [6].
GATA3 levels have previously been correlated with expres-
sion of ERα [7] and both were shown to reciprocally reg-
ulate one another at the transcriptional level in a cell-
culture based system in a cross-regulatory loop [8]. Fur-
thermore, in a meta-analysis of ERα 10 genes were pro-
posed as classifier of ERα positive breast tumours, listing
GATA3 as one of these [9]. A study has also compared
microarray experiments between estradiol-induced genes
from MCF-7 cells, and transfected GATA3-induced genes
from 293T cells to assess common upregulated genes [10].
In an elegant series of experiments utilizing MMTV-PyMT
(polyoma middle T antigen) mice it was first shown that
GATA3 expression was downregulated with the transition
from adenoma to carcinoma in mammary tumours, and
the expression was lost in lung metastases. Infection of the
MMTV-PyMT carcinomas with GATA3 upregulated mark-
ers of differentiation and resulted in a dramatic 27-fold
reduction in lung metasases [11]. Further crossing of these
mice with an inducible cre-WAP (whey acidic protein –
specific to luminal mammary epithelial cells) driven
knockout of GATA3, resulted in loss of markers of termi-
nal differentiation, detachment from the basal membrane
and apoptosis. This is consistent with the requirement of
GATA3 in differentiated tumours.
As described in a recent study known pathway partners
have been shown to yield a similar 'meta-analysis coex-
pression signature' i.e. having a significant overlap of
coexpressed genes can link proteins to the same pathways
[12]. Thus performing independent meta-analyses for
ERα and GATA3 (putative pathway partners), then com-
paring the results for overlapping genes would yield a
highly significant number of genes if these transcription
factors were in the same pathway. We report here not only
that these meta-analyses have a high degree of overlap,
but that genes identified are consistent with previous
reports of the ERα pathway regulation. Additionally we
show this correlation with previously identified ERα tar-
get genes by combining our meta-analysis data with both
RT-PCR and genome-wide location analysis from other
studies. These data not only confirm GATA3 as being a key
player in the ERα pathway, but also give fresh insights into
the pathway itself.
Methods
Meta-analysis
The following procedure was undertaken for independent
meta-analyses of GATA3 or ERα: a co-expression gene
search was performed within Oncomine [13]. Twenty-one
studies were chosen for analysis, most of which were
breast cancer studies. The top 400 coexpressed genes were
extracted and filtered to give one representative gene per
study (removing duplicates and ESTs). These filtered
genelists were then compared for repeating coexpressed
genes over multiple studies. The frequency cutoff was 3
studies (14% of 21 studies). This generated a meta-analy-
sis list for ERα or GATA3, which were then compared for
overlap. As the overlap was high the stringency was
increased to 4 studies (19%), the data of which is used for
Table 1. Gene names were obtained using Genecards [14].
Reporter gene assays
MCF-7 Cells were grown in DMEM (minus phenol-red)
with 10% charcoal-stripped FBS. SKBR3 were grown in
DMEM with 10% FBS. MUC1 (-881 to +13) was cloned as
a KpnI/XhoI fragment, and KRT18 (-2961 to +96) was
cloned as a KpnI/BglII fragment. Both were generated by
high-fidelity PCR from human genomic DNA (Roche),
and were ligated into pGL4.20 (Promega). pS2 reporter
has previously been described [15]. Luciferase reporter
gene assays were performed using standard protocols.
Here 200–400 ng reporter were transfected with 200 ng
pcDNA3 or pcDNA3-GATA3, and 3U/well of β-galactosi-
dase protein (Sigma) as transfection efficiency control.
Ten nM Tamoxifen (Sigma) was incubated for 14 h prior
to cell assay.
Results and Discussion
Using the Oncomine™ integrated cancer profiling data-
base GATA3 and ERα were searched for coexpressing
genes [13]. Coexpression data from 21 multi-array studies
was extracted and analysed, separately for ERα and
GATA3. While these studies varied in cancer-types, the
overwhelming majority extracted for analysis were breast-
cancer based [Additional file 1 and 2]. The frequency of
coexpressing genes over the 21 studies was determined
and the cutoff set to 3 studies or more (3 studies = 14%
frequency overlap – [see Additional file 1 and 2]). Next, to
ascertain the extent GATA3 may play a role in ERα path-
ways the frequency coexpression lists were compared for
overlap. Interestingly, there was an extensive overlap
between both GATA3 and ERα lists at the cutoff of 3 stud-
ies (Figure 1A). Increasing the cutoff to 4 or more studies
(almost one-fifth of the studies) did not change the rela-
tive overlap with respect to total gene numbers, with 43%
of the number of ERα coexpressed genes, and 56% of
GATA3 coexpressed genes represented in the overlap (Fig-
ure 1B). The overlap data with the frequency cutoff of 4
studies is shown in Table 1.
Every technique has its caveats, and the limitation here is
that we are assessing the common genes that are consist-
ently coexpressed with ERα and GATA3 over many differ-
ent human cancer studies. This implies that coexpressed
genes are in the same pathways as GATA3 and ERα. How-
ever, the meta-analyses can only infer association withinMolecular Cancer 2008, 7:49 http://www.molecular-cancer.com/content/7/1/49
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Table 1: Overlapping meta-analyses of GATA3 and ERα at cutoff of 4 studies (19%)
Overlap of ERα and GATA3 (4 or more studies)
ERα = 257, GATA3 = 194, OVERLAP = 108
ERα GATA3
GATA3 48% 100% GATA binding protein 3
ESR1 100% 67% estrogen receptor 1 (estrogen receptor alpha)
XBP1 38% 52% X-box binding protein 1
FOXA1 33% 52% forkhead box A1
FOXC1 19% 24% forkhead box C1
TFF1 33% 52% trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) [pS2]
TFF3 38% 67% trefoil factor 3 (intestinal)
NRIP1 19% 19% nuclear receptor interacting protein 1 (RIP140)
BCL2 43% 67% B-cell CLL/lymphoma 2
ACADSB 38% 48% acyl-Coenzyme A dehydrogenase, short/branched chain
LAF4 43% 38% lymphoid nuclear protein related to AF4
COX6C 38% 33% cytochrome c oxidase subunit VIc
FBP1 38% 33% fructose-1,6-bisphosphatase 1
IGF1R 38% 33% insulin-like growth factor 1 receptor
IRS1 33% 33% insulin receptor substrate 1
CELSR2 38% 38% cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila)
LRBA 38% 38% LPS-responsive vesicle trafficking, beach and anchor containing
NAT1 33% 57% N-acetyltransferase 1 (arylamine N-acetyltransferase)
SCNN1A 38% 57% sodium channel, nonvoltage-gated 1 alpha
DNAJC12 33% 48% DnaJ (Hsp40) homolog, subfamily C, member 12
RAB31 38% 19% RAB31, member RAS oncogene family
RABEP1 33% 43% rabaptin, RAB GTPase binding effector protein 1
SELENBP1 33% 33% selenium binding protein 1
FAAH 38% 33% fatty acid amide hydrolase
TNFSF10 38% 33% tumor necrosis factor (ligand) superfamily, member 10
SLC22A18 33% 24% solute carrier family 22 (organic cation transporter), member 1
SLC39A6 38% 57% solute carrier family 39 (zinc transporter), member 6 (Estrogen regulated protein LIV-1)
SLC40A1 33% 19% solute carrier family 40 (iron-regulated transporter), member 1
SLC9A3R1 19% 43% solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 1
SIAH2 33% 33% seven in absentia homolog 2 (Drosophila)
SERPINA3 38% 24% serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
SERPINA5 33% 19% serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 5
SERPINA6 19% 24% serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 6
ERBB3 33% 19% v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
ERBB4 19% 48% v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)
IL6ST 24% 38% interleukin 6 signal transducer (gp130, oncostatin M receptor)
KIAA0040 24% 24% KIAA0040 protein
KIAA0303 33% 43% Similar to Mouse serine/threonine protein kinase MAST205
KIAA0882 19% 19% KIAA0882 protein
ITPR1 24% 33% inositol 1,4,5-triphosphate receptor, type 1
INPP4B 24% 43% inositol polyphosphate-4-phosphatase, type II, 105kDa
JMJD2B 24% 48% jumonji domain containing 2B
C10orf116 24% 52% chromosome 10 open reading frame 116
ANXA9 19% 43% annexin A9
AR 19% 33% androgen receptor (dihydrotestosterone receptor; Kennedy disease)
CCND1 19% 48% cyclin D1 (PRAD1: parathyroid adenomatosis 1)
CCNG2 19% 24% cyclin G2
CA12 19% 38% carbonic anhydrase XII
CACNA1D 19% 33% calcium channel, voltage-dependent, L type, alpha 1D subunit
CACNA2D2 19% 43% calcium channel, voltage-dependent, alpha 2/delta subunit 2
DNALI1 24% 43% dynein, axonemal, light intermediate polypeptide 1
AGR2 19% 33% anterior gradient 2 homolog (Xenepus laevis)
GFRA1 33% 48% GDNF family receptor alpha 1
HPN 19% 43% hepsin (transmembrane protease, serine 1)
GREB1 19% 38% GREB1 protein
MAPT 19% 38% microtubule-associated protein tau
MLPH 24% 33% melanophilinMolecular Cancer 2008, 7:49 http://www.molecular-cancer.com/content/7/1/49
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the same pathways, and pathway coexpression at the RNA
level might not necessarily translate into protein level.
Nevertheless, our data are strongly supported by previous
knowledge of the ERα pathway.
A recent study identified 51 genes significantly upregu-
lated in ERα positive breast tumours, using a real-time
PCR based approach [16]. Attesting to the stringency of
the meta-analysis approach used here 32 of theses genes
were found to overlap with the ERα coexpression list,
while an identical number also overlapped with GATA3
KRT18 24% 33% keratin 18
PTPRT 24% 48% protein tyrosine phosphatase, receptor type, T
STC2 24% 33% stanniocalcin 2
SCUBE2 33% 24% CEGP1 protein
PTGER3 33% 24% prostaglandin E receptor 3 (subtype EP3)
PDCD4 33% 24% programmed cell death 4 (neoplastic transformation inhibitor)
MUC1 33% 29% mucin 1, transmembrane
NPY1R 33% 29% neuropeptide Y receptor Y1
FLJ20366 38% 24% hypothetical protein FLJ20366
TLE3 33% 29% transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila)
13CDNA73 24% 29% hypothetical protein CG003
AGTR1 24% 29% Angiotensin II receptor, type 1
ASAH1 24% 29% N-acylsphingosine amidohydrolase (acid ceramidase) 1
BF 24% 24% B-factor, properdin
ENPP1 24% 29% ectonucleotide pyrophosphatase/phosphodiesterase 1
QDPR 24% 29% quinoid dihydropteridine reductase
C9orf116 19% 29% chromosome 9 open reading frame 116
CYFIP2 19% 29% cytoplasmic FMR1 interacting protein 2
GRIA2 19% 29% glutamate receptor, ionotropic, AMPA 2
GSTM3 19% 29% Glutathione S-transferase M3 (brain)
ACOX2 19% 29% acyl-Coenzyme A oxidase 2, branched chain
LRIG1 19% 29% leucine-rich repeats and immunoglobulin-like domains 1
PLAT 19% 29% plasminogen activator, tissue
MAGED2 19% 29% Melanoma antigen family D, 2
THRAP2 19% 29% thyroid hormone receptor associated protein 2
MSX2 24% 24% msh homeo box homolog 2 (Drosophila)
UGCG 24% 24% UDP-glucose ceramide glucosyltransferase
ALCAM 19% 24% activated leukocyte cell adhesion molecule
ALDH4A1 19% 24% aldehyde dehydrogenase 4 family, member A1
ABCA3 24% 19% ATP-binding cassette, sub-family A (ABC1), member 3
LOC51760 19% 24% B/K protein
PRSS23 19% 24% protease, serine, 23
RHOH 24% 19% ras homolog gene family, member H
TFAP2B 19% 24% transcription factor AP-2 beta (activating enhancer binding protein 2 beta)
WFDC2 24% 19% WAP four-disulfide core domain 2
ANGPTL1 19% 19% angiopoietin-like 1
BCAS1 19% 19% breast carcinoma amplified sequence 1
CYP2B6 19% 19% cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6
EML2 19% 19% echinoderm microtubule associated protein like 2
FLNB 19% 19% filamin B, beta (actin binding protein 278)
GPR160 19% 19% G protein-coupled receptor 160
LU 19% 19% Lutheran blood group (Auberger b antigen included)
MRPS30 19% 19% mitochondrial ribosomal protein S30
PTE2B 19% 19% peroxisomal acyl-CoA thioesterase 2B
RERG 19% 19% RAS-like, estrogen-regulated, growth inhibitor
RNASE4 19% 19% ribonuclease, RNase A family, 4
RNF110 19% 19% polycomb group ring finger 2 (MEL-18)
SEMA3C 19% 19% sema domain, immunoglobulin domain (Ig), short basic domain, (semaphorin) 3C
SULT2B1 19% 19% sulfotransferase family, cytosolic, 2B, member 1
TPBG 19% 19% trophoblast glycoprotein
TPD52 19% 19% tumor protein D52
KAL1 19% 19% Kallmann syndrome 1 sequence
After individual Oncomine meta-analysis of 21 studies both lists of coexpressing genes, for GATA3 and ERα were compared for overlap. Overlap 
greater than 30% frequency (7 studies) is shown in bold. Overlap list is arranged by percent frequency.
Table 1: Overlapping meta-analyses of GATA3 and ERα at cutoff of 4 studies (19%) (Continued)Molecular Cancer 2008, 7:49 http://www.molecular-cancer.com/content/7/1/49
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(Table 2). This was reflected in a similar study comparing
ERα over-expressed transcripts in both oligonucleotide
microarray and SAGE platforms [17], where 27 genes
common to the ERα pathway are represented here in our
common ERα:GATA3 meta-analysis comparison [see
Additional file 3]. These data not only acted as wide-rang-
ing external validation for the individual meta-analyses,
but also confirmed the extent of the involvement of
GATA3 in ERα pathways.
Furthermore, when compared to a list of genome-wide
promoters shown to be bound by ERα in MCF-7 cells [18]
or on chromosomes 21 and 22 [19], 23 were identified in
the ERα meta-analysis list, while 27 were identified within
the GATA3 list (Table 3). This again supports both the
validity of the meta-analysis technique used here, and the
role of GATA3 in ERα pathways. It is also possible that the
overlap would be even higher if the ERα genomic location
analysis were performed on a pool of human ERα-positive
breast tumour samples as opposed to a cell-culture model
system. While not to detract from the power of a model
system such as MCF-7 there are likely to be a great many
differences between a homogeneous cell monolayer and a
3-dimensional cancer made up of a heterogeneous cell
population.
Of the 10 classifier genes previously identified in a meta-
analysis of ERα, the same 4 were identified in both meta-
analyses of this study (ESR1, GATA3, FOXA1, SLC39A6)
[9]. Once again this adds credence to the high-quality data
obtained in our current meta-analyses.
Implicating GATA3 in control of some of these gene prod-
ucts is a microarray experiment performed after overex-
Table 2: Comparison of GATA3 and ERα meta-analyses, and RT-
PCR study
GATA3 Oncomine ERα Oncomine
ESR1 44
GATA3 44
TFF1 44
TFF3 44
FOXA1 44
XBP1 44
IL6ST 44
KRT18 44
AR 44
BCL2 44
CCND1 44
RERG 44
ERBB4 44
NAT1 44
SLC39A6 44
DNAJC12 44
HPN 44
CYP2B6 44
CA12 44
STC2 44
ACADSB 44
LRBA 44
PTPRT 44
SULT2B1 44
MYB 44
SEMA3B 44
RET 44
SLC7A2 44
RABEP1 4
IGFBP4 4
CGA 4
GJA1 4
PGR 4
RARRES 4
BBC3 4
LOC255743 4
51 genes were identified as being upregulated in ERα-positive breast 
tumours in a recent study by Tozlu et al, and are compared with the 
Oncomine meta-analysis lists for ERα and GATA3, showing a 
significant overlap. 4 shows that this gene is represented.
Venn diagram showing overlap between ERα and GATA3  meta-analyses Figure 1
Venn diagram showing overlap between ERα and 
GATA3 meta-analyses. (A) Overlap when the frequency 
cutoff is 3 studies (14%). (B) Overlap when the frequency 
cutoff is 4 studies (19%).Molecular Cancer 2008, 7:49 http://www.molecular-cancer.com/content/7/1/49
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pression of GATA3 in 293T cells [20]. After expression of
GATA3 elevated levels of TFF1,  TFF3,  KRT18,  FOXA1,
SLC9A3R1, TPD52, BCAS1 were observed, all of which we
identified here for both GATA3 and ERα meta-analyses.
While 293T are not breast cancer cells, it raises the ques-
tion of how many more of our predicted pathway partners
of GATA3 would be identified if the microarray were
repeated in cells such as MCF-7 which also retain high
ERα expression. In the example of SLC9A3R1 (NHERF1)
which is a putative tumour suppressor, it was shown to
increase growth of 2 breast cancer cell lines when knocked
down by shRNA [21]. If GATA3 does help to control
expression of NHERF1 this might be one mechanism con-
sistent with its role in the less-aggressive differentiated
luminal A breast cancers. Another example is BCAS1
(NABC1) which is overexpressed in breast carcinomas but
downregulated in colorectal tumours [22,23]. Indeed,
overexpression of NABC1 did not result in changes in cell-
cycle or anchorage-dependent growth properties in
NIH3T3 cells, implying it may not be intrinsically onco-
genic [24].
As GATA3 is expressed in, and regulates, luminal epithe-
lial cells and has also been shown to regulate the MUC1
gene it is no surprise that MUC1 is also mostly expressed
in luminal breast epithelial cells as well as other glandular
epithelia [25]. MUC1, when abnormally expressed, leads
to a loss of both cell-extracellular and cell-cell contacts. It
has also been shown that MUC1 levels can be regulated by
estrogen and ERα can bind putative binding sites derived
from the MUC1 promoter in-vitro [26]. Here we reveal that
both GATA3 and ERα coexpress with MUC1 acting as fur-
ther validation of the meta-analysis technique used here.
Furthermore, transfected GATA3 can activate a MUC1 pro-
moter reporter in MCF-7 cells, even in the presence of
Tamoxifen i.e. independently to ERα activation. This acti-
vation could be repeated in the ERα-negative breast cancer
cell line SKBR3 (Figure 2). The activation of ERα pathway
genes was also observed with pS2 (TFF1) and KRT18
reporters (Figure 2). These data indicate that GATA3 can
have its own impact on the ERα pathway and is not just
acting indirectly via ERα.
It has also been postulated that, as the deletion of GATA3
in mammary primordia (by K14-Cre) resulted in an ina-
bility to form mammary placodes is similar to that of loss
of LEF1, Msx1 and Msx2 these may all be intertwined in a
transcriptional network [4,27]. It is of interest that in our
Table 3: Comparison of GATA3 and ERα meta-analyses with previously reported binding sites (by ChIP-chip analysis)
ERα ChIP-chip: GATA3 Oncomine ERα ChIP-chip: ERα Oncomine
ABCA3 ABCA3
ALDH3B2 ANXA9
ANXA9 BTRC
EPS8 C2
ESR1 CYP51A1
FLJ20152 ESR1
FOXA1 FLJ13710
GREB1 FOXA1
GTF2H2 GREB1
LOC51760 KCNAB2
MGC11242 LOC51760
MGP MB
NAV3 MGC11242
NQO1 MSP
PDZK1 SEMA3B
PHF15 SLC27A2
RTN1 SLC7A2
SEMA3B STARD10
SLC27A2 STK39
SLC7A2 TFF1
SLC7A8 TFF3
STARD10 NRIP1
STK39 RUNX1
TFF1
TFF3
TOMM40
NRIP1
Oncomine meta-analysis data for GATA3 or ERα was compared both to a promoter list published by Laganiere et al, (P = 0.05), and to a 
chromosome array list of 30 genes identified by Carroll et al. The overlap is shown and common overlap between ERα and GATA3 is shown in 
bold.Molecular Cancer 2008, 7:49 http://www.molecular-cancer.com/content/7/1/49
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present study we observe MSX2 coexpression both with
GATA3 and ERα, which helps to support this notion.
Using the meta-analysis data presented it is easy to build
up transcriptional networks such as this and all of the data
presented strongly supports (1) the quality of the meta-
analysis results, (2) the concept that GATA3 is firmly
entrenched within ERα pathways. Future in-depth analy-
sis of the data presented may lead to novel aspects of ERα
or GATA3 regulated pathways, and help to understand the
etiology of ERα-positive breast cancers, and management
of their outcomes.
Conclusion
While GATA3 has been identified previously in a meta-
analysis of ERα only 10 genes were identified in total [9].
Here we give an extensive list of coexpressed ERα genes
and for the first time a reciprocal meta-analysis for GATA3
has been performed, and the results compared for over-
lap. This overlap was considerable, confirming the impor-
tant role of GATA3 in the ERα pathway. The vital question
raised is whether GATA3 is crucial to the ERα pathway
only by regulation of ERα levels, or through further con-
trol of ERα-regulated genes in concert with ERα itself. The
GATA3 overexpression microarray experiment in 293T
cells, and our reporter gene assays certainly implies the
latter [20]. Genome-wide location analysis (ChIP-chip) of
GATA3 in a well-established ERα system such as MCF-7
cells, as well as specific analysis of the ERα pathway in
GATA3 conditional knockout mice will yield vital infor-
mation regarding the extent that GATA3 is integral to the
ERα pathway.
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GATA3 can activate ERα pathway promoter reporters Figure 2
GATA3 can activate ERα pathway promoter reporters. GATA3 can activate MUC1, pS2, or keratin 18 promoter 
reporters, in ERα-positive MCF-7 cells (even in the presence of tamoxifen – TAM), or in ERα-negative SKBR3 cells.Publish with BioMed Central    and   every 
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